Migraine and Depression Share Common Neuropeptide Pathways — CGRP, Substance P, and Neuropeptide Y | Research

The takeaway

Migraine and depression share overlapping biological mechanisms involving CGRP, PACAP, substance P, neuropeptide Y, orexins, serotonin, sex hormones, and immune pathways — explaining their strong bidirectional clinical relationship.

2.5× depression risk in migraine
Shared neuropeptide mechanisms (CGRP, PACAP, substance P, NPY, orexins) explain this strong bidirectional association

What the researchers found

Multiple neuropeptide systems (CGRP, PACAP, substance P, neuropeptide Y, orexins) provide overlapping biological substrates for both migraine and depression, explaining their strong bidirectional clinical relationship.

Why it matters

Treating migraine without addressing depression (and vice versa) leads to poorer outcomes. Understanding shared neuropeptide mechanisms could enable dual-action therapies — drugs that treat both conditions by targeting common pathways like CGRP or PACAP.

The numbers in context

Migraine patients are 2.5x more likely to develop depression; risk is higher in chronic migraine and migraine with aura; bidirectional relationship.

How the study worked

Comprehensive narrative review of epidemiological, clinical, and molecular evidence linking migraine and depression through shared biological mechanisms.

Who was studied

Patients with comorbid migraine and depression (general review)

What this study cannot tell us

Narrative review — no new data. Causation vs correlation for shared mechanisms is difficult to establish. Not all migraine patients have depression and vice versa. Individual neuropeptide contributions to each condition are not fully quantified.

How to read the evidence

Moderate evidence — well-supported review integrating epidemiological data with mechanistic evidence from multiple neuropeptide systems.

When this study was published

Published in 2024. Integrates latest neuropeptide research including CGRP and PACAP findings.

The bigger picture

The neuropeptide overlap between migraine and depression suggests that anti-CGRP therapies may have unexplored mood benefits, and that depression treatments targeting shared peptide systems could improve migraine. This reframes both conditions as part of a shared neuropeptide dysregulation spectrum.

Questions still open

Do anti-CGRP migraine therapies improve depressive symptoms in comorbid patients?
Could PACAP-targeting drugs treat both migraine and depression simultaneously?
Should psychiatric screening be mandatory for all chronic migraine patients?

Common questions

Why do so many people with migraines also have depression?

Because the two conditions share the same brain chemical pathways. Neuropeptides like CGRP (the target of new migraine drugs), substance P, and neuropeptide Y are involved in both pain processing and mood regulation. When these systems are disrupted, both migraine and depression can result.

Could migraine drugs help with depression too?

Possibly — since CGRP and other neuropeptides targeted by migraine therapies also play roles in mood, treating one condition might benefit the other. Some migraine patients report mood improvements on CGRP antibodies, but this hasn't been formally studied in depression trials yet.

Read the original research

Understanding the Biological Relationship between Migraine and Depression.

Biomolecules, 14(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Viudez-Martínez, Adrián; Torregrosa, Abraham B; Navarrete, Francisco; García-Gutiérrez, María Salud. (2024). Understanding the Biological Relationship between Migraine and Depression.. Biomolecules, 14(2). https://doi.org/10.3390/biom14020163